Formulation of Nanoparticle-Eluting Stents by a Cationic Electrodeposition Coating Technology. Efficient Nano-Drug Delivery via Bioabsorbable Polymeric Nanoparticle-Eluting Stents in Porcine Coronary Arteries

JACC: Cardiovascular Interventions

Volumn 2, Issue 4, 2009, Pages 277-283

  Nakano, Kaku ^a   Egashira, Kensuke ^a   Masuda, Seigo ^a   Funakoshi, Kouta ^a   Zhao, Gang ^b   Kimura, Satoshi ^a   Matoba, Tetsuya ^a   Sueishi, Katsuo ^a   Endo, Yasuhisa ^d   Kawashima, Yoshiaki ^c   Hara, Kaori ^e   Tsujimoto, Hiroyuki ^e   Tominaga, Ryuji ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

^e Hosokawa Powder Technology Research Institute   (Japan)

Author keywords

drug delivery system; nanotechnology; restenosis; smooth muscle cells; stents

Indexed keywords

CHITOSAN; FLUORESCEIN ISOTHIOCYANATE; METAL; NANOPARTICLE; POLYGLACTIN; POLYMER; SOLVENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; EMULSION; ENCAPSULATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SWINE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ABSORBABLE IMPLANTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; CATIONS; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; KINETICS; LACTIC ACID; MALE; MATERIALS TESTING; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NANOPARTICLES; POLYGLYCOLIC ACID; PROSTHESIS DESIGN; STAINLESS STEEL; SUS SCROFA;

EID: 64749102952     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.08.023     Document Type: Article

References (23)

1. Babapulle M.N., and Eisenberg M.J. Coated stents for the prevention of restenosis: Part I. Circulation 106 (2002) 2734-2740
2. Babapulle M.N., and Eisenberg M.J. Coated stents for the prevention of restenosis: Part II. Circulation 106 (2002) 2859-2866
3. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary-artery stents. N Engl J Med 354 (2006) 483-495
4. Laskey W.K., Yancy C.W., and Maisel W.H. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 115 (2007) 2352-2357
5. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 356 (2007) 325-328
6. Shuchman M. Trading restenosis for thrombosis?. New questions about drug-eluting stents. N Engl J Med 355 (2006) 1949-1952
7. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
8. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
9. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
10. Klugherz B.D., Jones P.L., Cui X., et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 18 (2000) 1181-1184
11. Walter D.H., Cejna M., Diaz-Sandoval L., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110 (2004) 36-45
12. Ohtani K., Egashira K., Nakano K., et al. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 114 (2006) 2773-2779
13. Egashira K., Nakano K., Ohtani K., et al. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol 27 (2007) 2563-2568
14. Wickline S.A., Neubauer A.M., Winter P., Caruthers S., and Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26 (2006) 435-441
15. Niwa T., Takeuchi H., Hino T., Kunou N., and Kawashima Y. In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 83 (1994) 727-732
16. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., and Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 102 (2005) 373-381
17. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., and Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 16 (2002) 1217-1226
18. van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
19. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., and Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 808-816
20. Ohtani K., Usui M., Nakano K., et al. Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther 11 (2004) 1273-1282
21. Egashira K., Zhao Q., Kataoka C., et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90 (2002) 1167-1172
22. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 41 (2003) 834-841
23. Miller R.A., Brady J.M., and Cutright D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J Biomed Mater Res 11 (1977) 711-719